RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date— —Resolves previously disclosed manufacturing delay of ORLADEYO ®
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent — —
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Bank of America Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 4:40 p.m. ET.
RESEARCH TRIANGLE PARK, N.C., April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m.